)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Kura Oncology (KURA) investor relations material
Kura Oncology Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary4 Nov, 2025
Executive summary
Ziftomenib advanced with NDA accepted by FDA for relapsed/refractory NPM1-mutated AML; PDUFA date set for November 30, 2025, and pivotal Phase 3 KOMET-017 trials initiated targeting over 50% of AML patients.
Positive clinical data for ziftomenib in both relapsed/refractory and newly diagnosed AML, with high remission and MRD negativity rates, and a favorable safety profile; two oral presentations accepted for the 2025 ASH Annual Meeting.
Collaboration with Kyowa Kirin for global development and commercialization, with $330M upfront and $75M in milestones received as of Q3 2025; commercial teams fully mobilized and launch readiness completed.
Strategic focus on advancing precision oncology pipeline, including farnesyl transferase inhibitors darlifarnib and tipifarnib, showing promising safety and efficacy in solid tumors and head and neck cancer.
Financial highlights
Collaboration revenue for Q3 2025 was $20.8 million, up from zero in Q3 2024; $50.1 million for the nine months ended September 30, 2025.
R&D expenses rose to $67.9 million from $41.7 million year-over-year; G&A expenses increased to $32.8 million from $18.2 million.
Net loss for Q3 2025 was $74.1 million, compared to $54.4 million in Q3 2024; net loss for the nine months was $197.7 million.
Cash, cash equivalents, and short-term investments totaled $609.7 million pro forma as of September 30, 2025, including recent milestone payments.
Total operating expenses for Q3 2025 were $100.7 million, up from $59.9 million in Q3 2024.
Outlook and guidance
Cash and investments expected to fund operations through end of 2027 and support ziftomenib program through topline KOMET-017 results.
Anticipates $315 million in near-term milestone payments, including a substantial payment upon ziftomenib commercial launch.
Key upcoming milestones include FDA decision, ASH data presentations, and further clinical data releases in 2026.
Ziftomenib AML program's target patient reach?
Next major clinical step for FTI program?
Funding strategy for KOMET-017 topline data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Kura Oncology earnings date
Status Update8 Dec, 2025
Next Kura Oncology earnings date
Status Update8 Dec, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage